LEASES |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Leases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LEASES | NOTE 14 – LEASES
On July 25, 2024, the Company entered into and closed the Scienture Merger. Pursuant to the Scienture Merger Agreement, the Company acquired right of use asset value of $61,578 and right of use liability of $61,886 on the acquisition date together with all the assets and liabilities of Scienture. In August 2026, the Company exercised its option under its existing office sublease with Saptalis Pharmaceuticals, LLC, which commenced on October 1, 2023, with an initial term ending July 31, 2026, to extend the term for an additional five years through August 31, 2031. Monthly rent during the extended term is $3,600 for the first 12 months, increasing 4% annually beginning August 1, 2027. Upon exercise of the option, the Company remeasured the lease and recognized a right-of-use asset and corresponding operating lease liability of $167,967, measured using an incremental borrowing rate of 15.5%.
The table below reconciles the fixed component of the undiscounted cash flows for and the total remaining years to the lease liabilities recorded in the consolidated balance sheet as of September 30, 2026.
Supplemental balance sheet information related to leases are as follows:
For the three months ended September 30, 2026, and 2025, total operating lease expense was $11,338 and $8,906, respectively, which is included in general and administrative expenses in the unaudited condensed consolidated statements of operations.
For the nine months ended September 30, 2026, and 2025, total operating lease expense was $25,077 and $68,103, respectively, which is included in general and administrative expenses in the unaudited condensed consolidated statements of operations.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||